Form 4: Revolution Medicines General Counsel Sells Shares Under 10b5-1 Plan

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,406 shares of common stock at $40.5 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jeff Cislini, the General Counsel of Revolution Medicines, sold 2,406 shares of common stock on January 21, 2025.
• The sale was executed at a price of $40.5 per share.
• This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on March 20, 2024.
• Following the transaction, Cislini beneficially owns 39,222 shares, which includes 36,204 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity and is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned sale of shares.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The sale of shares by a General Counsel is not unusual and is often part of their overall compensation and financial planning.
• Similar filings are regularly made by executives at comparable biotech companies such as Gilead Sciences, Amgen, and Regeneron.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates any significant concern.

Key Dates

Keywords

Form 4, insider trading, 10b5-1 plan, stock sale, Revolution Medicines, RVMD, Jeff Cislini, General Counsel